- Joel
Lexchin is a
professor emeritus at the York
University Faculty of
Health where he
taught about pharmaceutical policy, an ****ociate
Professor in the...
- Therapie. 76 (6): 715–723. doi:10.1016/j.therap.2018.02.004. PMID 29609830.
Lexchin, Joel (15
March 2005). "Drug
withdrawals from the
Canadian market for safety...
-
Treatment for Type 2 Diabetes". fda.gov. 13 May 2022.
Retrieved 2022-06-30.
Lexchin, Joel (November 2016). "How Safe and
Innovative Are First-in-class Drugs...
- doi:10.3978/j.issn.2072-1439.2014.09.01. PMC 4178073. PMID 25276402.
Lexchin J,
Grootendorst P (2004). "Effects of
prescription drug user fees on drug...
-
Complex /
Stanley Wohl.
First edition. New York:
Harmony Book, 1984: 85-98
Lexchin J,
Grootendorst P.
Effects of
Prescription Drug User Fees on Drug and Health...
- US$1.3
billion (not
including marketing expenses).
Professors Light and
Lexchin reported in 2012, however, that the rate of
approval for new
drugs has...
-
Policy Studies, Queen's University. p. 40. ISBN 978-1-55339-439-6. Joel
Lexchin (27
October 2016).
Private Profits versus Public Policy: The Pharmaceutical...
- shpsc.2011.07.003. PMID 22035723.
Roseman M,
Milette K, Bero LA,
Coyne JC,
Lexchin J,
Turner EH,
Thombs BD (2011), "Reporting of
Conflicts of
Interest in...
- PMID 17506338. S2CID 26915448.
Archived from the
original (PDF) on 2013-05-21.
Lexchin, Joel; Bero, Lisa A; Djulbegovic, Benjamin; Clark,
Otavio (2003-05-31)...
- i5955. doi:10.1136/bmj.i5955. PMID 27815253. S2CID 43604202.
Lundh A,
Lexchin J,
Mintzes B,
Schroll JB, Bero L, et al. (Cochrane
Methodology Review Group)...
